Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877903 · ClinicalTrials.gov registry record · Phase 2
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
A Phase 2 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00877903 is a Phase 2 study that has completed, run by Mesoblast. The registered enrollment target is 220 participants.
The verdict
NCT00877903, a Phase 2 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.
Interventions
- DRUG Placebo
- DRUG Prochymal®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2009-03-30 |
| Est. Completion | 2016-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877903
The ClinicalTrials.gov registry entry for NCT00877903 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00877903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00877903 about?
NCT00877903 is a clinical study titled "Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)". The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.
What is the current status of trial NCT00877903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2009-03-30. Estimated completion is 2016-03-14.
What interventions are being tested in trial NCT00877903?
The interventions under investigation include: Placebo (DRUG), Prochymal® (DRUG).
Who is sponsoring clinical trial NCT00877903?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.